Analyst Price Targets — SPRY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 9, 2026 10:56 am | — | Northland Securities | $25.00 | $8.27 | TheFly | Northland starts disruptor ARS Pharmaceuticals with an Outperform |
| March 10, 2026 10:22 am | Roanna Ruiz | Leerink Partners | $26.00 | $9.28 | StreetInsider | ARS Pharmaceuticals Inc (SPRY) PT Raised to $26 at Leerink Partners |
| November 4, 2025 12:53 pm | Kyle Bauser | Roth Capital | $30.00 | $8.42 | TheFly | ARS Pharmaceuticals resumed with a Buy at Roth Capital |
| September 26, 2025 2:02 pm | — | Raymond James | $32.00 | $9.69 | TheFly | Raymond James positive on ARS Pharmaceuticals after weekly data |
| August 19, 2024 5:06 pm | Josh Schimmer | Cantor Fitzgerald | $30.00 | $14.24 | TheFly | ARS Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald |
| August 12, 2024 4:28 pm | Strong Buy | Raymond James | $22.00 | $10.85 | TheFly | ARS Pharmaceuticals upgraded to Strong Buy from Outperform at Raymond James |
| July 25, 2024 6:30 am | Ryan Deschner | Raymond James | $18.00 | $10.40 | TheFly | ARS Pharmaceuticals initiated with an Outperform at Raymond James |
| March 5, 2024 6:07 am | Roanna Ruiz | Leerink Partners | $18.00 | $8.65 | StreetInsider | Leerink Partners Upgrades ARS Pharmaceuticals Inc (SPRY) to Outperform |
| December 13, 2022 6:10 am | — | Leerink Partners | $14.00 | $7.12 | Benzinga | SVB Leerink Initiates Coverage On ARS Pharmaceuticals with Outperform Rating, Announces Price Target of $14 |
Latest News for SPRY
neffy offers a new delivery method for epinephrine in Canada for adults and children ( > 30 kg) living with severe allergic reactions
Children were previously required to weigh ≥33 lbs. and
Bamco Inc. NY grew its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) by 3,071.3% in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,268,532 shares of the company's stock after acquiring an additional 1,228,532 shares during the period. Bamco Inc. NY owned about
ARS Pharmaceuticals, Inc. maintains a Hold rating as neffy's commercial uptake remains slow despite FDA approval and a robust marketing push. SPRY reported 2025 revenues of $84.3m, a net loss of $171.3m, and plans to sustain high SG&A spending to accelerate U.S. market share. Management offers no 2026 revenue guidance, raising concerns about breakeven prospects and ongoing competition from established and emerging…
ARS Pharmaceuticals, Inc. (SPRY) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SPRY.
U.S. House Trading
No House trades found for SPRY.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.